Li A H, Rosenquist R, Forestier E, Lindh J, Roos G
Department of Medical Biosciences, Pathology, Umeå University, 90187 Umeå, Sweden.
Leuk Res. 2001 Dec;25(12):1033-45. doi: 10.1016/s0145-2126(01)00072-8.
Genetic instability has important implications for detection of minimal residual disease (MRD) when the target is a clonal genetic marker revealed at diagnosis. A successful MRD detection approach requires a stable marker and for lymphoid leukemias clonal rearrangements of immunoglobulin (Ig) and T cell receptor (TCR) genes are commonly used. In the present study, Ig heavy chain (IgH) and TCR (gamma and delta) genes were studied in 18 consecutive, relapsing precursor-B ALL patients. At least one clonal rearrangement was found in all cases at presentation (IgH 94%, TCRgamma 39% and TCRdelta 28%). An altered rearrangement pattern between diagnosis and relapse was demonstrated in 14 patients (78%). At least one stable molecular target was found in 13 out of 18 cases (72%). Clonal differences between diagnostic and relapse samples were explained by: (1) loss of original rearrangements; (2) V(H) to DJ(H) joining; (3) V(H) gene replacement; (4) appearance of new rearrangements. In two cases with apparently new IgH gene rearrangements at relapse extended sequencing of the diagnostic samples revealed minor clonal rearrangements identical to the relapse clones. Interestingly, one patient displayed instability on both the IgH and TCR gene loci, whereas a stable Igkappa rearrangement was found at presentation and relapse. These data show that clonal diversity is common in precursor-B ALL and strongly suggest that MRD detection should include multiple gene targets to minimize false-negative samples. Even so, five of our 18 relapse cases (28%) lacked stable clonal markers and should have been unsuitable for MRD detection.
当检测靶点是诊断时发现的克隆性遗传标志物时,基因不稳定对微小残留病(MRD)的检测具有重要意义。一种成功的MRD检测方法需要一个稳定的标志物,对于淋巴样白血病,免疫球蛋白(Ig)和T细胞受体(TCR)基因的克隆重排是常用的。在本研究中,对18例连续复发的前体B淋巴细胞白血病患者的Ig重链(IgH)和TCR(γ和δ)基因进行了研究。所有病例在初诊时均发现至少一种克隆重排(IgH 94%,TCRγ 39%,TCRδ 28%)。14例患者(78%)在诊断和复发之间表现出重排模式的改变。18例中有13例(72%)发现至少一个稳定的分子靶点。诊断和复发样本之间的克隆差异可解释为:(1)原始重排的丢失;(2)V(H)与DJ(H)连接;(3)V(H)基因替换;(4)新重排的出现。在两例复发时出现明显新的IgH基因重排的病例中,对诊断样本进行深度测序发现与复发克隆相同的微小克隆重排。有趣的是,一名患者的IgH和TCR基因位点均表现出不稳定性,而在初诊和复发时均发现稳定的Igκ重排。这些数据表明,克隆多样性在前体B淋巴细胞白血病中很常见,并强烈提示MRD检测应包括多个基因靶点,以尽量减少假阴性样本。即便如此,我们18例复发病例中有5例(28%)缺乏稳定的克隆标志物,本应不适用于MRD检测。